SCHEMBL4468341

SCHEMBL4468341

CC(C)(C)c1ccc(-c2nc3ccnc(N4CCNCC4)c3[nH]2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 2/20 0.47
KCNH2 Q12809 1/20 0.44
HRH4 Q9H3N8 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
HDAC6 Q9UBN7 2/20 0.43
PRMT5 O14744 1/20 0.41
HTR2C P28335 2/20 0.40
TNKS O95271 2/20 0.40
TNKS2 Q9H2K2 2/20 0.40
PARP1 P09874 1/20 0.40
AURKA O14965 1/20 0.39
NPY5R Q15761 1/20 0.38
HTR1A P08908 1/20 0.38
HTR1D P28221 1/20 0.38
HTR1B P28222 1/20 0.38
HTR6 P50406 1/20 0.38
GNRHR P30968 2/20 0.38
TRPV1 Q8NER1 2/20 0.38
GCGR P47871 1/20 0.37
EPHX2 P34913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13324655 0.80 HDAC6 (0.50) PRKCIHDAC6TNKSTNKS2HTR1A
SCHEMBL4466673 0.79 AURKA (0.46) PRKCIHDAC6PRMT5AURKAHTR1A
SCHEMBL4464448 0.78 GNRHR (0.65) HDAC6GNRHRTACR2HRH2OPRM1
SCHEMBL4474514 0.78 GNRHR (0.47) HDAC6HTR1AHTR1DHTR1BHTR6
SCHEMBL13864530 0.77 GNRHR (0.51) HDAC6GNRHRTACR2HRH2OPRM1
SCHEMBL4465985 0.75 GNRHR (0.63) HDAC6PARP1GNRHRTACR2HRH2
SCHEMBL4470282 0.75 HDAC6 (0.51) HRH4HDAC6TNKSTNKS2PARP1
SCHEMBL13864558 0.72 GNRHR (0.46) HDAC6HTR1AHTR1DHTR1BGNRHR
SCHEMBL13867370 0.71 GNRHR (0.45) HDAC6GNRHRTACR2HRH2OPRM1
SCHEMBL3274724 0.68 GNRHR (0.70) GNRHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538113-B2 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor WYETH (US) 2009-05-26 US disclosed
US-7538113-B2 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor WYETH (US) 2009-05-26 US disclosed
US-7538113-B2 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor WYETH (US) 2009-05-26 US disclosed
US-20060189618-A1 4-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor WYETH (US) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189618-A1 4-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor GNRHR, LHCGR, FSHR PRKCI 4001/4885KCNH2 339/4885HRH4 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.